There are currently 1046 clinical trials in Ann Arbor, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Michigan, University of Michigan Comprehensive Cancer Center, University of Michigan Health System and Saint Joseph Mercy Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
NCT04120493
Recruiting
This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase I/II, randomized, multicenter, multiple dose, double-blind, imitation surgery, first-in-human (FIH) study. Cohort 3 participants will receive either high or low dose (1:1 randomization). Participants enrolled in Cohort 3 will also receive an immunosuppression regimen consisting of dexamethasone, sirolimus, and rituximab.
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
04/29/2024
Locations: University of Michigan Department of Neurology, Ann Arbor, Michigan
Conditions: Huntington's Disease
Register for Updates
Sensory Testing of Multiple Forms of Spinal Cord Stimulation for Pain
NCT04732325
Recruiting
Doctors sometimes treat chronic pain with devices that send mild electrical currents into the spinal cord. This type of treatment is referred to as neurostimulation. A common form of neurostimulation therapy is spinal cord stimulation (SCS). In this study, researchers want to learn more about how SCS affects pain processing and relieves pain. The researchers will examine multiple forms of SCS in chronic pain patients who are receiving SCS from their own doctors as part of their standard of care.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Chronic Pain, Failed Back Surgery Syndrome, Complex Regional Pain Syndromes, Neuropathic Pain
Register for Updates
What is the Potential Impact of Reviewing Post-procedure Images With Patients Following Interventional Spine Procedures.
NCT05884684
Recruiting
The purpose of this study is to explore the impact of spine physicians reviewing post-procedural fluoroscopic images with patients. The outcome measure to be assessed will be the potential impact the patient satisfaction and the patient's global impression of change (PGIC) 2 weeks after the spine procedure.
Gender:
All
Ages:
All
Trial Updated:
04/28/2024
Locations: University of Michigan - Burlington Building, Ann Arbor, Michigan
Conditions: Patient Satisfaction
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: VA Ann Arbor Healthcare System, Ann Arbor, Michigan +1 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
NCT05254834
Recruiting
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
Gender:
All
Ages:
30 years and above
Trial Updated:
04/26/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cancer
Register for Updates
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065
Recruiting
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response c... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
04/26/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Spinal Cord Glioma, Recurrent Malignant Central Nervous System Neoplasm, CNS Tumor, Central Nervous System Tumor, World Health Organization (WHO) Grade III Glioma
Register for Updates
CHIlled Platelet Study "CHIPS"
NCT04834414
Recruiting
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Gender:
All
Ages:
Between 0 days and 84 years
Trial Updated:
04/26/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Acute Blood Loss
Register for Updates
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
NCT02584270
Recruiting
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality in a robust scientific randomized prospective clinical trial. Positive outcomes from this study have the potential to dramatically alter the most common issues of oral cancer therapy, namely speech and swallowing functions. Patients will have been diagnosed with a cancer lesion on their tongue requiring surgery and removal of part of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: University of Michigan Department of Oral and Maxillofacial Surgery and Hospital Dentistry, Ann Arbor, Michigan
Conditions: Tongue Neoplasms, Tongue Cancer, Oral Cancer
Register for Updates
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568
Recruiting
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Gender:
All
Ages:
80 years and below
Trial Updated:
04/25/2024
Locations: The Regents of the University of Michigan, Ann Arbor, Michigan
Conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Register for Updates
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT04471974
Recruiting
This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular growth in certain types of tumors, including castrate resistant prostate cancer. Enzalutamide has been shown to block testosterone from reaching prostate cancer cells by binding to a receptor on prostate cancer cells, calle... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
NCT03942653
Recruiting
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Salivary Gland Carcinoma
Register for Updates
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489
Recruiting
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
Register for Updates